Description
Class A61P : THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
Subclass 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P 7/00)
A61P 3/00
Sub-Class
Stats
- 539 US PATENTS IN FORCE
- 264 US APPLICATIONS PENDING
- 143 Total Patent Owners
- 11,067 TOTAL INVENTORS
Recent Patents
| Patent # | Title | Filing Date | Issue Date | Patent Owner |
|---|---|---|---|---|
| 12264142 | Heterocyclic compounds | Oct 21, 20 | Apr 01, 25 | FLORATEK PHARMA SA |
| 12264137 | 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors | Mar 10, 22 | Apr 01, 25 | Valo Health, Inc. |
| 12257230 | Composition comprising naphthoquinone-based compound as active ingredient, for preventing or ameliorating fatigue, cachexia, pain, cognitive decline and hematopoietic stem cell reduction which are side effects related to anticancer drug treatment | Apr 28, 17 | Mar 25, 25 | NADIANBIO Ltd. |
| 12258597 | Methods and compositions for therapeutic protein delivery | Feb 07, 19 | Mar 25, 25 | Regeneron Pharmaceuticals, Inc. |
| 12251407 | in preventing and/or treating metabolic diseases | Dec 07, 18 | Mar 18, 25 | BGI SHENZHEN |
| 12251430 | Compositions and methods for treating Pompe disease | Feb 08, 21 | Mar 18, 25 | Genzyme Corporation |
| 12252470 | Lipids and nanoparticle compositions thereof | Apr 24, 24 | Mar 18, 25 | Generation Bio Co. |
| 12252703 | Closed-ended linear duplex DNA for non-viral gene transfer | Jun 01, 21 | Mar 18, 25 | UNIVERSITY OF MASSACHUSETTS; Voyager Therapeutics, Inc.; |
| 12246002 | Pharmaceutical composition for prevention or treatment of circadian rhythm-related disorders, comprising oxyiminomethylbenzene derivative as active ingredient | Sep 27, 19 | Mar 11, 25 | Korea University Research and Business Foundation; KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION; |
| 12239674 | LRH05 isolate, and composition including the same and use thereof | Jun 17, 21 | Mar 04, 25 | SYNBIO TECH INC. |
| 12233088 | Bis-choline tetrathiomolybdate for treating Wilson Disease | Aug 23, 22 | Feb 25, 25 | Alexion Pharmaceutical, Inc. |
| 12226443 | Polyphenol composition and method of its use and manufacture in the treatment of metabolic disorders | Jan 14, 19 | Feb 18, 25 | Vidya Herbs, Inc. |
| 12213956 | Method of treating fatty acid oxidation disorders using omega3/omega6 unsaturated or branched chain fatty acids | Jul 28, 21 | Feb 04, 25 | University of Pittsburgh—of the Commonwealth System of Higher Education |
| 12213979 | Biomarkers of methotrexate-induced immune tolerance | Dec 21, 18 | Feb 04, 25 | Genzyme Corporation |
| 12214083 | Pharmaceutical composition and administrations thereof | Jul 20, 23 | Feb 04, 25 | Vertex Pharmaceuticals Incorporated |
| 12215139 | Preparation method and application of high-purity plant-derived recombinant human serum albumin | Nov 22, 23 | Feb 04, 25 | WUHAN HEALTHGEN BIOTECHNOLOGY CORP. |
| 12208077 | Synergistic composition for potentiating stabilized ATP | Apr 06, 22 | Jan 28, 25 | Celagenex Research (India) Pvt. Ltd. |
| 12201658 | Viral gene therapy as treatment for cholesterol storage disease or disorder | Sep 25, 20 | Jan 21, 25 | The United States of America as represented by the Secretary Department of Health and Human Services |
| 12202901 | Cannabinoid receptor type 1 (CB1) antibodies, encoding nucleic acid molecules thereof and methods of use thereof | Apr 29, 19 | Jan 21, 25 | Takeda Pharmaceutical Company Limited |
| 12186329 | Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes | Aug 23, 19 | Jan 07, 25 | President and Fellows of Harvard College; The Brigham and Women's Hospital, Inc.; |
Recent Publications
| Publication # | Title | Filing Date | Pub Date | Patent Owner |
|---|---|---|---|---|
| 2025/0114,406 | METHODS AND COMPOSITIONS RELATING TO CHONDRISOMES FROM BLOOD PRODUCTS | Jan 04, 24 | Apr 10, 25 | Not available |
| 2025/0114,421 | METHOD FOR IMPROVING HEALTH CONDITION OF MAMMAL OR FARM ANIMAL | Apr 27, 23 | Apr 10, 25 | Not available |
| 2025/0108,072 | NON-NATURALLY OCCURING THREE-DIMENSIONAL (3D) BROWN ADIPOSE-DERIVED STEM CELL AGGREGATES, AND METHODS OF GENERATING AND USING THE SAME | Sep 10, 24 | Apr 03, 25 | Not available |
| 2025/0108,128 | CRISPR-MEDIATED HUMAN GENOME EDITING WITH VECTORS | Jan 25, 23 | Apr 03, 25 | Not available |
| 2025/0099,473 | TREATMENT OF MITOCHONDRIAL DISEASES | May 01, 24 | Mar 27, 25 | Not available |
| 2025/0101,401 | ENGINEERED METHIONINE GAMMA LYASE VARIANTS | Sep 05, 24 | Mar 27, 25 | Not available |
| 2025/0090,526 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | Apr 22, 24 | Mar 20, 25 | Not available |
| 2025/0073,181 | REDUCTION OF ADIPOSE TISSUE | Sep 30, 24 | Mar 06, 25 | Not available |
| 2025/0073,210 | Use of Ergothioneine for Enhancing Glutathione Level | Dec 30, 22 | Mar 06, 25 | Not available |
| 2025/0066,454 | COMPLEX COACERVATES OF LACTOFERRIN AND OSTEOPONTIN | Dec 16, 22 | Feb 27, 25 | Not available |
| 2025/0059,257 | PREPARATION METHOD AND APPLICATION OF HIGH-PURITY PLANT-DERIVED RECOMBINANT HUMAN SERUM ALBUMIN | Oct 23, 24 | Feb 20, 25 | Not available |
| 2025/0049,952 | IMPROVED GENE THERAPY CONSTRUCTS FOR THE TREATMENT OF PROPIONIC ACIDEMIA CAUSED BY MUTATIONS IN PROPIONYL-COA CARBOXYLASE ALPHA | Dec 29, 22 | Feb 13, 25 | The United States of America as represented by the Secretary Department of Health and Human Services |
| 2025/0051,740 | TREATMENT OF MUCOPOLYSACCHARIDOSIS II WITH RECOMBINANT HUMAN IDURONATE-2-SULFATASE (IDS) PRODUCED BY HUMAN NEURAL OR GLIAL CELLS | May 09, 24 | Feb 13, 25 | REGENXBIO Inc. |
| 2025/0051,780 | COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING | May 09, 22 | Feb 13, 25 | Not available |
| 2025/0041,445 | GENE THERAPY FOR TREATMENT OF MUCOPOLYSACCHARIDOSIS IIIA | Nov 11, 22 | Feb 06, 25 | The Trustees of the University of Pennsylvania; Amicus Therapeutics, Inc.; |
| 2025/0041,455 | ANTI-TFR:GAA AND ANTI-CD63:GAA INSERTION FOR TREATMENT OF POMPE DISEASE | Jul 26, 24 | Feb 06, 25 | Not available |
| 2025/0043,261 | METHODS AND COMPOSITIONS FOR TREATING ANGIOPOIETIN-LIKE 3 (ANGPTL3) RELATED CONDITIONS | Jul 11, 24 | Feb 06, 25 | Not available |
| 2025/0043,285 | Mammalian ATG8 Proteins and ATG9A Direct Sealing of Autophagosomal Membranes | Jul 02, 24 | Feb 06, 25 | Not available |
| 2025/0043,000 | NON-CYTOTOXIC MODIFIED CELLS AND USE THEREOF | Aug 21, 24 | Feb 06, 25 | The National Institute for Biotechnology in the Negev Ltd. |
| 2025/0032,642 | CRISPR-MEDIATED TRANSGENE INSERTION IN NEONATAL CELLS | Feb 02, 23 | Jan 30, 25 | Not available |
Top Owners in This Subclass
| Upgrade to the Professional Level to view Top Owners for this Subclass.Learn More |
|---|
Patents Issued To Date - By Filing Year
Average Time to Issuance
- 31 Months (last 2 years Issuances)
- 31 Months (last 5 years Issuances)